Close

Pfizer Provides Evidence To Back The Clearance Of Prevnar 20

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

The Best Type of Accreditation for a Telehealth Provider

Telehealth and remote patient monitoring services are becoming more...

Pharmaceutical Contract Sales Market to Hit $26.24B by 2034

Contract Sales Organizations: Transforming Pharma Companies Contract sales organizations –...

What Are the Benefits of Outsourcing to a Clinical Research Organization?

Have you ever wondered if outsourcing certain tasks could...

What’s Missing from Drug Warning Labels? A Look at Patient Safety

Drug warning labels are meant to protect patients. But...

Although Pfizer beat Merck to sell its next-generation pneumococcal vaccination, it lost a more important battle in June when the FDA said its competitor may provide its next-generation shot to new-borns and young children.

Two months later, Pfizer, playing catch-up, has reacted with clinical evidence that might pave the way for the approval of its injection, Prevnar 20, for use in babies. According to a news statement, Pfizer stated it hopes to submit its Biologics License Application to the FDA for Prevnar 20 clearance before the end of the year.

Prevnar 20 is roughly a year behind Merck’s next-generation shot in the paediatric population. In August of last year, Merck released its phase 3 findings for Vaxneuvance usage in newborns. An unforeseen roadblock occurred in March when the FDA postponed its decision over Vaxneuvance, delaying the clearance by three months.

Pfizer may be able to beat Merck once their vaccine is licenced because Vaxneuvance offers protection from 15 serotypes.

All 20 of the serotypes covered by Prevnar 20 met the study’s non-inferiority criteria, triggering immunological responses in the phase 3 trial. In addition, the trial assessed immunological responses following the third Prevnar 20 treatment in a four-dose series, with 14 of the 20 serotypes qualifying. According to the statement, of the six that didn’t, two fell short more severely and four missed by a significant margin.

In July 2021, Merck received the first approval for the use of Vaxneuvance in adults. However, given that they make up 80% of the profitable market, children are the crucial demographic. Prevnar 13 sales last year totalled $5.3 billion.

Latest stories

Related stories

The Best Type of Accreditation for a Telehealth Provider

Telehealth and remote patient monitoring services are becoming more...

Pharmaceutical Contract Sales Market to Hit $26.24B by 2034

Contract Sales Organizations: Transforming Pharma Companies Contract sales organizations –...

What Are the Benefits of Outsourcing to a Clinical Research Organization?

Have you ever wondered if outsourcing certain tasks could...

What’s Missing from Drug Warning Labels? A Look at Patient Safety

Drug warning labels are meant to protect patients. But...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back